Isis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Genzyme Corporation

Rosanne M Crooke

Mark J Graham

Susan M Freier

Kristina M Lemonidis

Kenneth W Dobie

Sanjay Bhanot

Andrew T Watt

Diane Tribble

Richard Lee

Marc Lim

Andrew Dibble

Eric E Swayze

Punit P Seth

Thazha P Prakash

Kristina Lemonidis Tarbet

Kristina L Lemonidis

Adam Mullick

Veronica J Alexander

Steven Mah

Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Methods and compositions for modulating apolipoprotein (a) expression

Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

Methods for treating hypercholesterolemia

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.

Modulation of angiopoietin-like 3 expression

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.

Compositions and methods for modulating angiopoietin-like 3 expression

Methods and compositions for modlating apolipoprotein (A) expression

Provided herein are improved compounds, compositions and associated methods for reducing expression of ApoCIII mRNA and protein in a subject having, or at risk of having, diabetes. Also provided herein are compounds, compositions and associated methods improving peripheral insulin sensitivity, a lipid profile and a diabetes profile as well as reducing free fatty acids and intramyocellular triglyceride deposition.

Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile

Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.

Modulation of apolipoprotein C-III expression

Growing community of inventors

Carlsbad, CA, United States of America

Rosanne M Crooke